{"success":true,"data":{"pressRelease":{"id":"3334","rtpr_id":"nACSMYMfza","ticker":"COSM","exchange":"NASDAQ","all_tickers":["COSM"],"title":"Cosmos Health Introduces the \"18 Series\" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products","author":"ACCESSWIRE","published_at":"2026-04-21T16:51:45.465Z","article_body":"*\nScience-first nutraceutical platform: Every \"18\" product must clear three\ncriteria before reaching market - a patented ingredient, peer-reviewed\nclinical evidence, and the exact dose studied in clinical trials; a bar the\nvast majority of the supplement industry cannot meet\n*\nThree products introduced, $7.8 billion addressable market: Noor18(™),\nLiv18(™), and Cur18(™) - targeting healthy aging & beauty, liver &\nmetabolic support, and inflammation & mobility across three of the\nfastest-growing health categories in the U.S.\n*\nInstitutional-grade scientific standard: Patented ingredients, published\nrandomized controlled trials, exact clinical dosing - built to the standard of\ninstitutional science, not marketing\n*\nCompounding platform value, 18 clinically validated products targeted: Each\nnew \"18\" product retroactively strengthens every existing one - the portfolio\nbecomes more valuable with every addition\n\nCHICAGO, IL / ACCESS Newswire (https://www.accessnewswire.com/) / April 21,\n2026 / Cosmos Health Inc. (https://pr.report/kuip) (\"Cosmos Health\" or the\n\"Company\") (NASDAQ:COSM) (https://pr.report/5zI9BhPZ), a diversified,\nvertically integrated global healthcare group, today announced the U.S.\nintroduction of the \"18 Series\" - a premium nutraceutical platform designed to\nmeet growing consumer demand for clinically validated health solutions.\n(https://app.accessnewswire.com/imagelibrary/cfe048cb-77aa-418e-936d-57678dc2c72e/1159432/picture1.png)\n1. The 18 Series - Overview\n\nCosmos Health Inc. is executing a disciplined, science-first strategy to build\nthe what we believe to be most credible clinical supplement portfolio in the\nUnited States. The cornerstone of this strategy is the '18 Series' - a\nportfolio of products where every brand carries a shared scientific promise:\npatented ingredient, published clinical evidence, exact clinically studied\ndose.\n\nThe '18 Series' is not a product line in the traditional sense. It is a\ncertification - a quality threshold that each product must clear before it\nearns the right to carry the designation. This creates a compounding brand\nequity effect: each new '18' introduction strengthens the credibility of every\nexisting '18' product, and the portfolio as a whole becomes more valuable than\nthe sum of its parts.\n\nThree products are currently in the '18 Series': Noor18(™) (marine collagen,\nanti-aging), Liv18(™) (liver fat support), and Cur18(™) (next-generation\ncurcumin). Together, they address a combined U.S. supplement market\nopportunity exceeding $7.8 billion, across three of the fastest-growing health\ncategories in the country - with a long-term strategic target of 18 products\nspanning key biological systems.\n\n 18 Series Products  Combined Market                                           Clinical Studies                    Patents                        Portfolio Target                                    \n 3 introduced        $7.8B+ U.S. addressable market across current categories  7+ peer-reviewed published studies  3 patented active ingredients  18 products targeted across key biological systems  \n\n2. The \"18\" - A Scientific Standard, Not a Marketing Claim\n\nThe choice of '18' as the unifying symbol of the Company's premium portfolio\nis deliberate and multi-layered. It is simultaneously a scientific reference,\na portfolio classification system, and a philosophical statement about what\nthis company believes supplements should be.\n\n2.1 The Scientific Origin\n\nThe '18' traces its origin to a landmark pharmacokinetic study - an\n18-subject, randomized, double-blind crossover trial that demonstrated\nsubstantially enhanced bioavailability of curcumin versus the standard\nextract. That number became a symbol: the moment science proved that the\nsupplement market had been under-delivering on its biggest promises.\n\n2.2 The Portfolio Classification\n\nWithin the Cosmos Health brand architecture, the '18' suffix is a\ncertification mark. A product earns the '18' designation only when it\nsatisfies all three criteria simultaneously:\n*\nPatented: The active ingredient is protected by an active patent covering\ncomposition, manufacturing process, and/or health application - preventing\ngeneric competition and ensuring supply exclusivity\n*\nPublished: At least one peer-reviewed, published randomized controlled trial\nor pharmacokinetic study in a reputable medical journal substantiates the\nprimary health claim at the commercial dose\n*\nExact dose: The product delivers the same milligram quantity used in the\npublished study - no underdosing, no proprietary blends that obscure\ningredient amounts\n\n2.3 The Philosophy - Chai (חַי)\n\nIn Hebrew tradition, the number 18 represents Chai - meaning 'life.' It is one\nof the most universally recognized symbols of vitality, protection, and\nrenewal across cultures. Cosmos Health does not use this symbolism in a\nreligious context. Rather, the '18' embodies the brand's core mission: every\nproduct in the series is designed to protect and renew a critical biological\nsystem - liver health, collagen architecture, cellular inflammation response.\nThe '18' is life, made scientifically rigorous.\n\n3. The 18 Series - Product by Product\n\nNoor18(™) - Marine Collagen · Anti-Aging · Beauty from Within\n\nNoor18(™) is powered by a patented marine collagen tripeptide ingredient\nderived from wild-caught fish using patented enzymatic hydrolysis technology.\nThe product targets the single largest consumer driver in the premium\nsupplement market: visible anti-aging results - reduced wrinkles, thicker\nhair, stronger nails, improved joint comfort.\n\nNoor18(™) enters the $1.6 billion U.S. collagen supplement market as the\npremium clinical alternative, directly benchmarked against leading DTC\ncollagen brands.\n\n Noor18 (™)Profile    Detail                                                                                                           \n Clinical Evidence    IRB-approved RCT: 64 women, 12 weeks, 25% wrinkle reduction                                                      \n Key Claims           Reduces wrinkles · Improves skin hydration & elasticity · Thickens hair · Strengthens nails · Joint support      \n Market               $1.6B+ U.S. collagen supplement market · Women 35-65 primary demographic                                         \n\nLiv18(™) - Liver Fat Support · Metabolic Health · NAFLD/MASLD\n\nLiv18(™) is powered by a patented botanical blend clinically demonstrated to\nreduce liver fat accumulation in two independent randomized controlled trials.\nIt enters the U.S. market at a critical moment: NAFLD/MASLD now affects more\nthan 30% of U.S. adults, there is no FDA-approved drug for the condition, and\nconsumer awareness of liver health is rising sharply.\n\nLiv18™ is the only consumer supplement in the U.S. market delivering this\npatented botanical blend at the exact clinical dose - the pure,\nsingle-ingredient, clinically dosed version.\n\n Liv18 (™)Profile    Detail                                                                                                               \n Clinical Evidence   2 published RCTs: Study 1 (Type 2 Diabetes, 14 weeks) + Study 2 (Non-diabetics >50, 12 weeks)                        \n Key Claims          ↓15% liver fat (>50yr subjects) · ↓ALT/AST enzymes · 2× weight loss vs placebo                                       \n Competitive Moat    Only consumer supplement at the exact clinical dose in the U.S. market · No FDA drug for NAFLD - no Rx competition   \n Market              $4.6B U.S. liver health supplement market · 7% CAGR through 2030                                                     \n\nCur18(™) - Next-Gen Curcumin Therapy · Inflammation · Joint · Gut · Mood\n\nCur18(™) is powered by a patented curcumin extract, with GRAS\nself-affirmation underway, supported by published pharmacokinetic and clinical\nefficacy data. It enters one of the largest and most consumer-familiar\nsupplement categories in the United States: the $1.63 billion\nturmeric/curcumin market - with a product that is categorically better than\nanything on shelf.\n\nThe curcumin category is vast but deeply commoditized. The overwhelming\nmajority of turmeric supplements use standard extracts with known absorption\nlimitations.Cur18(™) is the disruptive alternative: same botanical source,\ndramatically enhanced bioavailable payload, GRAS self-affirmation underway,\npatented technology, and two peer-reviewed studies. The bioavailability story\nis one of the most compelling science-to-consumer narratives in the supplement\nindustry.\n\n Cur18 (™)Profile    Detail                                                                                              \n Bioavailability     39× enhanced free curcumin bioavailability vs standard curcumin extract                             \n Clinical Evidence   Pharmacokinetic study (Medicine, 2021, n=18) + Osteoarthritis RCT (Nutrients, 2021, n=101)          \n GRAS Status         GRAS self-affirmation process completed by an independent expert panel, pending final confirmation  \n Key Claims          Anti-inflammatory · Joint pain · Gut health · Mood · Post-exercise recovery · Antioxidant           \n Competitive Moat    39× bioavailability - the most powerful efficacy claim in the curcumin category                     \n Market              $1.63B turmeric supplement market (2025) → $3.12B by 2033 · 8.5% CAGR                               \n\n4. Brand Architecture - How the Portfolio Compounds\n\nThe '18 Series' is architected for compounding brand value. Each product\nintroduction does not merely add a revenue line - it strengthens the entire\nportfolio's credibility. This is the fundamental difference between a product\nline and a platform.\n\n4.1 Shared Visual Identity\n\nEvery '18' product shares the same visual language: Deep Navy × Prestige Gold\n× Parchment - premium, clinical, and unmistakably consistent. On shelf and\nonline, a consumer who knows Noor18(™) immediately recognizes Liv18(™) and\nCur18(™) as members of the same trusted family.\n\n4.2 Cross-Product Consumer Journey\n\nThe target consumer for the '18 Series' is the health-conscious adult aged\n35-65 who is willing to pay a premium for supplements that work - and who is\nfrustrated by the gap between what the supplement industry promises and what\nit delivers. This consumer is the same person across all three products: they\nwant better skin AND better liver health AND better inflammation control. The\n'18 Series' is designed to be a complete premium health stack - not three\nseparate purchase decisions, but one brand relationship.\n\n4.3 The Compounding Effect\n\nEach new '18' introduction creates retroactive value for existing products.\nWhen Cur18(™) was introduced, it told the world that the company that\nintroduced Liv18(™) has now applied the same standard to curcumin. When the\nnext '18' is introduced, it will tell the world that the standard continues to\nhold. The brand is intended to be self-reinforcing. Investors, retailers, and\nconsumers will learn to trust the '18' before they know what it contains.\n\n Platform Driver             Effect                                                                                                                         \n Unified brand identity      Premium, consistent visual language across all products reinforces scientific credibility at shelf and online                  \n Cross-category reach        Each new product opens a new high-growth health category under the same trusted standard                                       \n Compounding credibility     Every new '18' introduction retroactively strengthens existing products - the portfolio appreciates with each addition         \n Consumer stack opportunity  The same 35-65 health-conscious consumer is the target across all three products - one relationship, multiple revenue streams  \n\nGreg Siokas, CEO of Cosmos Health, stated: \"We chose 18 because it earns its\nmeaning twice. Once in the laboratory, where science changed what we know\nabout absorption. And once in the deepest tradition of human wellness, where\n18 has always meant life. When consumers see the '18', they should know: this\nproduct has been held to the highest standard we know how to set.\n\nI started this company with one conviction: that the health supplement\nindustry was systematically under-delivering on its promises, and that the\nonly way to change that was to build products on a foundation of real science.\nNot marketing claims. Not proprietary blends designed to hide underdosing.\nReal peer-reviewed, published, patented science. The '18 Series' is the\nembodiment of that conviction. Every product we have introduced under the '18'\ndesignation - Noor18(™), Liv18(™), Cur18(™) - has met a standard that\nthe vast majority of the supplement industry cannot match. A published RCT. A\npatented ingredient. The exact dose used in the study. That is not the norm in\nthis industry. It should be. And we are going to make it the norm, one product\nat a time. For our shareholders, I want to be direct: we are not building a\nsupplement company. We are building a clinical evidence platform, dressed as a\nconsumer brand. The '18' is our moat. Every new product that earns the\ndesignation makes the ones before it more valuable. The addressable market is\nenormous - $7.8 billion across just three categories. We have only begun. The\npipeline is deep, the standard will never drop. The 18 Series is how Cosmos\nHealth becomes a household name - not by selling more, but by being trusted\nmore.\"\n\nAbout Cosmos Health Inc.\n\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://pr.report/kuiv) and X (https://pr.report/kuiw).\n\nForward-Looking Statements\n\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas \"believes,\" \"expects,\" \"anticipates,\" \"intends,\" \"projects,\" \"estimates,\"\n\"plans,\" and similar expressions, or future or conditional verbs such as\n\"will,\" \"should,\" \"would,\" \"may,\" and \"could,\" generally identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. These statements involve risks and uncertainties that may\nindividually or materially affect the matters discussed herein for a variety\nof reasons outside the Company's control, including, but not limited to: the\nCompany's ability to raise sufficient financing to implement its business\nplan; the effectiveness of its digital asset strategies, including\naccumulation and yield-generating activities; the impact of the war in Ukraine\nand ongoing conflicts in the Middle East and other regions on the Company's\nbusiness, operations, and the economy in general; and the Company's ability to\nsuccessfully develop and commercialize its proprietary products and\ntechnologies. Readers are cautioned not to place undue reliance on these\nforward-looking statements, as actual results could differ materially from\nthose anticipated. Readers are encouraged to review the risk factors set forth\nin the Company's filings with the SEC, which are available at the SEC's\nwebsite (www.sec.gov). The Company disclaims any obligation to update or\nrevise forward-looking statements, whether as a result of any new information,\nfuture events, or otherwise.\n\nInvestor Relations Contact:\n\nBDG Communications\ncosm@bdgcommunications.com\n\nSOURCE: Cosmos Health Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-introduces-the-%2218-series%22-in-the-united-states-a-scien-1159432)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSMYMfza","title":"Cosmos Health Introduces the \"18 Series\" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products","author":"ACCESSWIRE","ticker":"COSM","created":"2026-04-21T16:51:45.465Z","tickers":["COSM"],"exchange":"NASDAQ","article_body":"*\nScience-first nutraceutical platform: Every \"18\" product must clear three\ncriteria before reaching market - a patented ingredient, peer-reviewed\nclinical evidence, and the exact dose studied in clinical trials; a bar the\nvast majority of the supplement industry cannot meet\n*\nThree products introduced, $7.8 billion addressable market: Noor18(™),\nLiv18(™), and Cur18(™) - targeting healthy aging & beauty, liver &\nmetabolic support, and inflammation & mobility across three of the\nfastest-growing health categories in the U.S.\n*\nInstitutional-grade scientific standard: Patented ingredients, published\nrandomized controlled trials, exact clinical dosing - built to the standard of\ninstitutional science, not marketing\n*\nCompounding platform value, 18 clinically validated products targeted: Each\nnew \"18\" product retroactively strengthens every existing one - the portfolio\nbecomes more valuable with every addition\n\nCHICAGO, IL / ACCESS Newswire (https://www.accessnewswire.com/) / April 21,\n2026 / Cosmos Health Inc. (https://pr.report/kuip) (\"Cosmos Health\" or the\n\"Company\") (NASDAQ:COSM) (https://pr.report/5zI9BhPZ), a diversified,\nvertically integrated global healthcare group, today announced the U.S.\nintroduction of the \"18 Series\" - a premium nutraceutical platform designed to\nmeet growing consumer demand for clinically validated health solutions.\n(https://app.accessnewswire.com/imagelibrary/cfe048cb-77aa-418e-936d-57678dc2c72e/1159432/picture1.png)\n1. The 18 Series - Overview\n\nCosmos Health Inc. is executing a disciplined, science-first strategy to build\nthe what we believe to be most credible clinical supplement portfolio in the\nUnited States. The cornerstone of this strategy is the '18 Series' - a\nportfolio of products where every brand carries a shared scientific promise:\npatented ingredient, published clinical evidence, exact clinically studied\ndose.\n\nThe '18 Series' is not a product line in the traditional sense. It is a\ncertification - a quality threshold that each product must clear before it\nearns the right to carry the designation. This creates a compounding brand\nequity effect: each new '18' introduction strengthens the credibility of every\nexisting '18' product, and the portfolio as a whole becomes more valuable than\nthe sum of its parts.\n\nThree products are currently in the '18 Series': Noor18(™) (marine collagen,\nanti-aging), Liv18(™) (liver fat support), and Cur18(™) (next-generation\ncurcumin). Together, they address a combined U.S. supplement market\nopportunity exceeding $7.8 billion, across three of the fastest-growing health\ncategories in the country - with a long-term strategic target of 18 products\nspanning key biological systems.\n\n 18 Series Products  Combined Market                                           Clinical Studies                    Patents                        Portfolio Target                                    \n 3 introduced        $7.8B+ U.S. addressable market across current categories  7+ peer-reviewed published studies  3 patented active ingredients  18 products targeted across key biological systems  \n\n2. The \"18\" - A Scientific Standard, Not a Marketing Claim\n\nThe choice of '18' as the unifying symbol of the Company's premium portfolio\nis deliberate and multi-layered. It is simultaneously a scientific reference,\na portfolio classification system, and a philosophical statement about what\nthis company believes supplements should be.\n\n2.1 The Scientific Origin\n\nThe '18' traces its origin to a landmark pharmacokinetic study - an\n18-subject, randomized, double-blind crossover trial that demonstrated\nsubstantially enhanced bioavailability of curcumin versus the standard\nextract. That number became a symbol: the moment science proved that the\nsupplement market had been under-delivering on its biggest promises.\n\n2.2 The Portfolio Classification\n\nWithin the Cosmos Health brand architecture, the '18' suffix is a\ncertification mark. A product earns the '18' designation only when it\nsatisfies all three criteria simultaneously:\n*\nPatented: The active ingredient is protected by an active patent covering\ncomposition, manufacturing process, and/or health application - preventing\ngeneric competition and ensuring supply exclusivity\n*\nPublished: At least one peer-reviewed, published randomized controlled trial\nor pharmacokinetic study in a reputable medical journal substantiates the\nprimary health claim at the commercial dose\n*\nExact dose: The product delivers the same milligram quantity used in the\npublished study - no underdosing, no proprietary blends that obscure\ningredient amounts\n\n2.3 The Philosophy - Chai (חַי)\n\nIn Hebrew tradition, the number 18 represents Chai - meaning 'life.' It is one\nof the most universally recognized symbols of vitality, protection, and\nrenewal across cultures. Cosmos Health does not use this symbolism in a\nreligious context. Rather, the '18' embodies the brand's core mission: every\nproduct in the series is designed to protect and renew a critical biological\nsystem - liver health, collagen architecture, cellular inflammation response.\nThe '18' is life, made scientifically rigorous.\n\n3. The 18 Series - Product by Product\n\nNoor18(™) - Marine Collagen · Anti-Aging · Beauty from Within\n\nNoor18(™) is powered by a patented marine collagen tripeptide ingredient\nderived from wild-caught fish using patented enzymatic hydrolysis technology.\nThe product targets the single largest consumer driver in the premium\nsupplement market: visible anti-aging results - reduced wrinkles, thicker\nhair, stronger nails, improved joint comfort.\n\nNoor18(™) enters the $1.6 billion U.S. collagen supplement market as the\npremium clinical alternative, directly benchmarked against leading DTC\ncollagen brands.\n\n Noor18 (™)Profile    Detail                                                                                                           \n Clinical Evidence    IRB-approved RCT: 64 women, 12 weeks, 25% wrinkle reduction                                                      \n Key Claims           Reduces wrinkles · Improves skin hydration & elasticity · Thickens hair · Strengthens nails · Joint support      \n Market               $1.6B+ U.S. collagen supplement market · Women 35-65 primary demographic                                         \n\nLiv18(™) - Liver Fat Support · Metabolic Health · NAFLD/MASLD\n\nLiv18(™) is powered by a patented botanical blend clinically demonstrated to\nreduce liver fat accumulation in two independent randomized controlled trials.\nIt enters the U.S. market at a critical moment: NAFLD/MASLD now affects more\nthan 30% of U.S. adults, there is no FDA-approved drug for the condition, and\nconsumer awareness of liver health is rising sharply.\n\nLiv18™ is the only consumer supplement in the U.S. market delivering this\npatented botanical blend at the exact clinical dose - the pure,\nsingle-ingredient, clinically dosed version.\n\n Liv18 (™)Profile    Detail                                                                                                               \n Clinical Evidence   2 published RCTs: Study 1 (Type 2 Diabetes, 14 weeks) + Study 2 (Non-diabetics >50, 12 weeks)                        \n Key Claims          ↓15% liver fat (>50yr subjects) · ↓ALT/AST enzymes · 2× weight loss vs placebo                                       \n Competitive Moat    Only consumer supplement at the exact clinical dose in the U.S. market · No FDA drug for NAFLD - no Rx competition   \n Market              $4.6B U.S. liver health supplement market · 7% CAGR through 2030                                                     \n\nCur18(™) - Next-Gen Curcumin Therapy · Inflammation · Joint · Gut · Mood\n\nCur18(™) is powered by a patented curcumin extract, with GRAS\nself-affirmation underway, supported by published pharmacokinetic and clinical\nefficacy data. It enters one of the largest and most consumer-familiar\nsupplement categories in the United States: the $1.63 billion\nturmeric/curcumin market - with a product that is categorically better than\nanything on shelf.\n\nThe curcumin category is vast but deeply commoditized. The overwhelming\nmajority of turmeric supplements use standard extracts with known absorption\nlimitations.Cur18(™) is the disruptive alternative: same botanical source,\ndramatically enhanced bioavailable payload, GRAS self-affirmation underway,\npatented technology, and two peer-reviewed studies. The bioavailability story\nis one of the most compelling science-to-consumer narratives in the supplement\nindustry.\n\n Cur18 (™)Profile    Detail                                                                                              \n Bioavailability     39× enhanced free curcumin bioavailability vs standard curcumin extract                             \n Clinical Evidence   Pharmacokinetic study (Medicine, 2021, n=18) + Osteoarthritis RCT (Nutrients, 2021, n=101)          \n GRAS Status         GRAS self-affirmation process completed by an independent expert panel, pending final confirmation  \n Key Claims          Anti-inflammatory · Joint pain · Gut health · Mood · Post-exercise recovery · Antioxidant           \n Competitive Moat    39× bioavailability - the most powerful efficacy claim in the curcumin category                     \n Market              $1.63B turmeric supplement market (2025) → $3.12B by 2033 · 8.5% CAGR                               \n\n4. Brand Architecture - How the Portfolio Compounds\n\nThe '18 Series' is architected for compounding brand value. Each product\nintroduction does not merely add a revenue line - it strengthens the entire\nportfolio's credibility. This is the fundamental difference between a product\nline and a platform.\n\n4.1 Shared Visual Identity\n\nEvery '18' product shares the same visual language: Deep Navy × Prestige Gold\n× Parchment - premium, clinical, and unmistakably consistent. On shelf and\nonline, a consumer who knows Noor18(™) immediately recognizes Liv18(™) and\nCur18(™) as members of the same trusted family.\n\n4.2 Cross-Product Consumer Journey\n\nThe target consumer for the '18 Series' is the health-conscious adult aged\n35-65 who is willing to pay a premium for supplements that work - and who is\nfrustrated by the gap between what the supplement industry promises and what\nit delivers. This consumer is the same person across all three products: they\nwant better skin AND better liver health AND better inflammation control. The\n'18 Series' is designed to be a complete premium health stack - not three\nseparate purchase decisions, but one brand relationship.\n\n4.3 The Compounding Effect\n\nEach new '18' introduction creates retroactive value for existing products.\nWhen Cur18(™) was introduced, it told the world that the company that\nintroduced Liv18(™) has now applied the same standard to curcumin. When the\nnext '18' is introduced, it will tell the world that the standard continues to\nhold. The brand is intended to be self-reinforcing. Investors, retailers, and\nconsumers will learn to trust the '18' before they know what it contains.\n\n Platform Driver             Effect                                                                                                                         \n Unified brand identity      Premium, consistent visual language across all products reinforces scientific credibility at shelf and online                  \n Cross-category reach        Each new product opens a new high-growth health category under the same trusted standard                                       \n Compounding credibility     Every new '18' introduction retroactively strengthens existing products - the portfolio appreciates with each addition         \n Consumer stack opportunity  The same 35-65 health-conscious consumer is the target across all three products - one relationship, multiple revenue streams  \n\nGreg Siokas, CEO of Cosmos Health, stated: \"We chose 18 because it earns its\nmeaning twice. Once in the laboratory, where science changed what we know\nabout absorption. And once in the deepest tradition of human wellness, where\n18 has always meant life. When consumers see the '18', they should know: this\nproduct has been held to the highest standard we know how to set.\n\nI started this company with one conviction: that the health supplement\nindustry was systematically under-delivering on its promises, and that the\nonly way to change that was to build products on a foundation of real science.\nNot marketing claims. Not proprietary blends designed to hide underdosing.\nReal peer-reviewed, published, patented science. The '18 Series' is the\nembodiment of that conviction. Every product we have introduced under the '18'\ndesignation - Noor18(™), Liv18(™), Cur18(™) - has met a standard that\nthe vast majority of the supplement industry cannot match. A published RCT. A\npatented ingredient. The exact dose used in the study. That is not the norm in\nthis industry. It should be. And we are going to make it the norm, one product\nat a time. For our shareholders, I want to be direct: we are not building a\nsupplement company. We are building a clinical evidence platform, dressed as a\nconsumer brand. The '18' is our moat. Every new product that earns the\ndesignation makes the ones before it more valuable. The addressable market is\nenormous - $7.8 billion across just three categories. We have only begun. The\npipeline is deep, the standard will never drop. The 18 Series is how Cosmos\nHealth becomes a household name - not by selling more, but by being trusted\nmore.\"\n\nAbout Cosmos Health Inc.\n\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://pr.report/kuiv) and X (https://pr.report/kuiw).\n\nForward-Looking Statements\n\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas \"believes,\" \"expects,\" \"anticipates,\" \"intends,\" \"projects,\" \"estimates,\"\n\"plans,\" and similar expressions, or future or conditional verbs such as\n\"will,\" \"should,\" \"would,\" \"may,\" and \"could,\" generally identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. These statements involve risks and uncertainties that may\nindividually or materially affect the matters discussed herein for a variety\nof reasons outside the Company's control, including, but not limited to: the\nCompany's ability to raise sufficient financing to implement its business\nplan; the effectiveness of its digital asset strategies, including\naccumulation and yield-generating activities; the impact of the war in Ukraine\nand ongoing conflicts in the Middle East and other regions on the Company's\nbusiness, operations, and the economy in general; and the Company's ability to\nsuccessfully develop and commercialize its proprietary products and\ntechnologies. Readers are cautioned not to place undue reliance on these\nforward-looking statements, as actual results could differ materially from\nthose anticipated. Readers are encouraged to review the risk factors set forth\nin the Company's filings with the SEC, which are available at the SEC's\nwebsite (www.sec.gov). The Company disclaims any obligation to update or\nrevise forward-looking statements, whether as a result of any new information,\nfuture events, or otherwise.\n\nInvestor Relations Contact:\n\nBDG Communications\ncosm@bdgcommunications.com\n\nSOURCE: Cosmos Health Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-introduces-the-%2218-series%22-in-the-united-states-a-scien-1159432)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-04-21T16:51:45.503528066Z","server_sent_at_ms":1776790305503},"received_at":"2026-04-21T16:51:45.663Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-introduces-the-%2218-series%22-in-the-united-states-a-scien-1159432"},"analysis":{"id":"2231","press_release_id":"3334","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Cosmos Health launched the \"18 Series\" nutraceutical platform in the U.S., introducing three products—Noor18, Liv18, and Cur18—focused on anti-aging, liver health, and inflammation.\n\nThe platform targets a combined $7.8 billion addressable market across these categories, utilizing a standard requiring patented ingredients, published trials, and exact clinical dosing.\n\nManagement aims to expand the portfolio to 18 validated products, positioning the brand as a premium, clinical alternative in the supplement industry.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Science-first platform launch targets multi-billion dollar supplement markets with clinical validation strategy."},"keyFigures":{"customDimensions":{"launched_products":3,"addressable_market_usd":"$7.8 billion","target_portfolio_products":18}},"quotedText":"When consumers see the '18', they should know: this product has been held to the highest standard we know how to set.","namedEntities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["18 Series","Noor18","Liv18","Cur18","Sky Premium Life","Mediterranation","bio-bebe","C-Sept","C-Scrub"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"$7.8 billion","context":"combined U.S. supplement market opportunity across current categories"},{"amount":"$1.6 billion","context":"U.S. collagen supplement market"},{"amount":"$4.6B","context":"U.S. liver health supplement market"},{"amount":"$1.63 billion","context":"turmeric/curcumin market (2025)"},{"amount":"$3.12B","context":"turmeric/curcumin market forecast by 2033"}]},"materialImpact":{"score":3,"reasoning":"Launch of a strategic science-first nutraceutical platform targeting a $7.8 billion addressable market, introducing three products designed to meet rigorous clinical standards."},"tickerRelevance":{"others":[],"primary":"COSM"},"eventTypeSecondary":[]},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Cosmos Health launched the \"18 Series\" nutraceutical platform in the U.S., introducing three products—Noor18, Liv18, and Cur18—focused on anti-aging, liver health, and inflammation.\n\nThe platform targets a combined $7.8 billion addressable market across these categories, utilizing a standard requiring patented ingredients, published trials, and exact clinical dosing.\n\nManagement aims to expand the portfolio to 18 validated products, positioning the brand as a premium, clinical alternative in the supplement industry.","key_figures":{"customDimensions":{"launched_products":3,"addressable_market_usd":"$7.8 billion","target_portfolio_products":18}},"named_entities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["18 Series","Noor18","Liv18","Cur18","Sky Premium Life","Mediterranation","bio-bebe","C-Sept","C-Scrub"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"$7.8 billion","context":"combined U.S. supplement market opportunity across current categories"},{"amount":"$1.6 billion","context":"U.S. collagen supplement market"},{"amount":"$4.6B","context":"U.S. liver health supplement market"},{"amount":"$1.63 billion","context":"turmeric/curcumin market (2025)"},{"amount":"$3.12B","context":"turmeric/curcumin market forecast by 2033"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T22:27:50.978Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.641Z"}},"durationMs":66643,"modelName":"glm-4.7"}}